IN-VITRO ACTIVITY OF CEFEPIME AND OTHER ANTIMICROBIALS - SURVEY OF EUROPEAN ISOLATES

被引：35

作者：

THORNSBERRY, C ^{[1
]}

BROWN, SD ^{[1
]}

YEE, YC ^{[1
]}

BOUCHILLON, SK ^{[1
]}

MARLER, JK ^{[1
]}

RICH, T ^{[1
]}

机构：

[1] INST MICROBIOL RES,FRANKLIN,TN

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1993年 / 32卷

关键词：

D O I：

10.1093/jac/32.suppl_B.31

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Cefepime, a new cephalosporin which has a broad-spectrum of activity was tested in vitro against 1961 Gram-positive and Gram-negative clinical isolates obtained from European hospitals. Cefepime was highly active against Gram-negative organisms, inhibiting over 94% of strains tested. The overall susceptibility rate for cefepime against all isolates was 81%. Cefepime was more active than any of the third-generation cephalosporins tested against species capable of producing type I β-lactamases, e.g. Enterobacter cloacae, Citrobacter freundii, and Enterobacter aero-genes. The activity of cefepime against Pseudomonas aeruginosa was similar to that of ceftazidime and substantially greater than those of cefotaxime and ceftnaxone. All cephalosporins except ceftazidime exhibited high activity against methicillin-susceptible Staphylococcus aureus but poor activity was observed against methicillin-resistant strains. Overall susceptibility to cefepime is lower in Europe than it is in North America. © 1993 The British Society for Antimicrobial Chemotheraphy.

引用

页码：31 / 53

页数：23

共 18 条

[1]

BAUERNFEIND A, 1991, INFECTION S5, V5, P264

[2] NOVEL METHOD FOR MEASUREMENT OF OUTER-MEMBRANE PERMEABILITY TO NEW BETA-LACTAMS IN INTACT ENTEROBACTER-CLOACAE CELLS [J].